These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 34367188)

  • 21. Cytokine profile, ferritin and multi-visceral involvement characterize macrophage activation syndrome during adult-onset Still's disease.
    Ruscitti P; Ursini F; Berardicurti O; Masedu F; Bozzalla Cassione E; Naldi S; Di Cola I; Di Muzio C; De Stefano L; Di Nino E; Navarini L; Vomero M; Bugatti S; Valenti M; Mariani E; Iagnocco A; Montecucco C; Giacomelli R; Cipriani P
    Rheumatology (Oxford); 2022 Dec; 62(1):321-329. PubMed ID: 35438139
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum S100A8/A9, but not follistatin-like protein 1 and interleukin 18, may be a useful biomarker of disease activity in adult-onset Still's disease.
    Kim HA; An JM; Nam JY; Jeon JY; Suh CH
    J Rheumatol; 2012 Jul; 39(7):1399-406. PubMed ID: 22660800
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interleukin 18: a biomarker for differential diagnosis between adult-onset Still's disease and sepsis.
    Priori R; Colafrancesco S; Alessandri C; Minniti A; Perricone C; Iaiani G; Palazzo D; Valesini G
    J Rheumatol; 2014 Jun; 41(6):1118-23. PubMed ID: 24786926
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TLR4 Endogenous Ligand S100A8/A9 Levels in Adult-Onset Still's Disease and Their Association with Disease Activity and Clinical Manifestations.
    Kim HA; Han JH; Kim WJ; Noh HJ; An JM; Yim H; Jung JY; Kim YS; Suh CH
    Int J Mol Sci; 2016 Aug; 17(8):. PubMed ID: 27537874
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neutrophil activation biomarker pentraxin 3 for diagnosis and monitoring of macrophage activation syndrome occurrence in adult-onset Still's disease.
    Zhu D; Chen L; Meng J; Wang M; Ma Y; Chen X; Xiao Y; Yi D; Shi H; Sun Y; Liu H; Cheng X; Su Y; Ye J; Chi H; Zhou Z; Yang C; Teng J; Jia J; Hu Q
    J Autoimmun; 2024 Apr; 144():103182. PubMed ID: 38460457
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytokine profile in adult-onset Still's disease: Comparison with systemic juvenile idiopathic arthritis.
    Inoue N; Shimizu M; Tsunoda S; Kawano M; Matsumura M; Yachie A
    Clin Immunol; 2016 Aug; 169():8-13. PubMed ID: 27263804
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Involvement of TLR7 MyD88-dependent signaling pathway in the pathogenesis of adult-onset Still's disease.
    Chen DY; Lin CC; Chen YM; Lan JL; Hung WT; Chen HH; Lai KL; Hsieh CW
    Arthritis Res Ther; 2013 Mar; 15(2):R39. PubMed ID: 23497717
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Elevated serum levels of interleukin-10 in adult-onset Still's disease are associated with disease activity.
    Sun Y; Wang Z; Chi H; Hu Q; Ye J; Liu H; Cheng X; Shi H; Zhou Z; Teng J; Yang C; Su Y
    Clin Rheumatol; 2019 Nov; 38(11):3205-3210. PubMed ID: 31236746
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anakinra in patients with treatment-resistant adult-onset Still's disease: four case reports with serial cytokine measurements and a review of the literature.
    Kötter I; Wacker A; Koch S; Henes J; Richter C; Engel A; Günaydin I; Kanz L
    Semin Arthritis Rheum; 2007 Dec; 37(3):189-97. PubMed ID: 17583775
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predominance of Th1 cytokine in peripheral blood and pathological tissues of patients with active untreated adult onset Still's disease.
    Chen DY; Lan JL; Lin FJ; Hsieh TY; Wen MC
    Ann Rheum Dis; 2004 Oct; 63(10):1300-6. PubMed ID: 15361391
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The specialized pro-resolving lipid mediator Protectin D1 affects macrophages differentiation and activity in Adult-onset Still's disease and COVID-19, two hyperinflammatory diseases sharing similar transcriptomic profiles.
    Navarini L; Vomero M; Currado D; Berardicurti O; Biaggi A; Marino A; Bearzi P; Corberi E; Rigon A; Arcarese L; Leuti A; Fava M; Fogolari M; Mattei A; Ruscitti P; Di Cola I; Sambuco F; Travaglino F; Angeletti S; Ursini F; Mariani E; Cipriani P; Agrò FE; Iagnocco A; Antonelli Incalzi R; Maccarrone M; Giacomelli R
    Front Immunol; 2023; 14():1148268. PubMed ID: 37153620
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interleukin-18 as an efficient marker for remission and follow-up in patients with inactive adult-onset Still's disease.
    Jung KH; Kim JJ; Lee JS; Park W; Kim TH; Jun JB; Yoo DH
    Scand J Rheumatol; 2014; 43(2):162-9. PubMed ID: 24134323
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Elevated circulating pro-inflammatory low-density granulocytes in adult-onset Still's disease.
    Liu Y; Xia C; Chen J; Fan C; He J
    Rheumatology (Oxford); 2021 Jan; 60(1):297-303. PubMed ID: 32757000
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interleukin-18 and fibroblast growth factor 2 in combination is a useful diagnostic biomarker to distinguish adult-onset Still's disease from sepsis.
    Koga T; Sumiyoshi R; Furukawa K; Sato S; Migita K; Shimizu T; Umeda M; Endo Y; Fukui S; Kawashiri SY; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Nonaka F; Yachie A; Kondo H; Maeda T; Kawakami A
    Arthritis Res Ther; 2020 May; 22(1):108. PubMed ID: 32381117
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased apoptosis of peripheral blood lymphocytes and its association with interleukin-18 in patients with active untreated adult-onset Still's disease.
    Chen DY; Hsieh TY; Hsieh CW; Lin FJ; Lan JL
    Arthritis Rheum; 2007 Dec; 57(8):1530-8. PubMed ID: 18050226
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum VEGF-C as an evaluation marker of disease activity in adult-onset Still's disease.
    Chen X; Hu QY; Wang M; Jia J; Teng J; Sun Y; Cheng X; Ye J; Su Y; Shi H; Chi H; Zhou Z; Liu T; Wang Z; Wan L; Qiao X; Wang F; Wu X; Yang C; Liu HL
    Rheumatol Int; 2022 Jan; 42(1):149-157. PubMed ID: 34499196
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The potential role of advanced glycation end products (AGEs) and soluble receptors for AGEs (sRAGE) in the pathogenesis of adult-onset still's disease.
    Chen DY; Chen YM; Lin CC; Hsieh CW; Wu YC; Hung WT; Chen HH; Lan JL
    BMC Musculoskelet Disord; 2015 May; 16():111. PubMed ID: 25956266
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Elevated serum gasdermin D N-terminal implicates monocyte and macrophage pyroptosis in adult-onset Still's disease.
    Nagai H; Kirino Y; Nakano H; Kunishita Y; Henmi R; Szymanski AM; Yoshimi R; Ombrello MJ; Nakajima H
    Rheumatology (Oxford); 2021 Aug; 60(8):3888-3895. PubMed ID: 33550379
    [TBL] [Abstract][Full Text] [Related]  

  • 39. sCD163 in AOSD: a biomarker for macrophage activation related to hyperferritinemia.
    Colafrancesco S; Priori R; Alessandri C; Astorri E; Perricone C; Blank M; Agmon-Levin N; Shoenfeld Y; Valesini G
    Immunol Res; 2014 Dec; 60(2-3):177-83. PubMed ID: 25388964
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum leucine-rich α2-glycoprotein is a useful biomarker for monitoring disease activity in patients with adult-onset Still's disease.
    Ha YJ; Kang EJ; Lee SW; Park YB; Lee SK; Song JS; Choi ST
    Scand J Rheumatol; 2015; 44(5):399-403. PubMed ID: 26079682
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.